Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

immunoglobulin G · Asceniv

Plasma-derived product · Immune activation · developed by ADMA Biologics

Approved FDA, Apr 2019
ADMA Developer
3 Registered trials

What is immunoglobulin G?

Immunoglobulin G (Asceniv, Bivigam) is a human plasma-derived intravenous immunoglobulin preparation. It is administered intravenously to provide passive immunity and support humoral immune response in patients with primary immune deficiency and other immunodeficiency conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Asceniv, Bivigam
Drug type
Plasma-derived product
Mechanism
Immune activation
Therapy area
Immunology
Developer
ADMA Biologics, Inc. (ADMA)
Also in trials of
EBS
FDA status
Approved as Asceniv (April 1, 2019), BLA125590

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05070455 Phase 4 Primary Immune Deficiency Unknown ADMA
NCT03164967 Phase 4 Humoral Immune Response Completed ADMA
NCT00845650 Phase 1/2 Anthrax Completed EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AnthraxHumoral Immune ResponsePrimary Immune Deficiency

More from ADMA Biologics

RI-002 FDA approved RI-001 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ADMA page.

Follow ADMA, the company behind immunoglobulin G

See ADMA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADMA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.